|
MechanismHeparin agonists |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
In patients with moderate dry eye syndrome is a three months treatment with with arabinogalactan monodose ophthalmic formulation 5% as safe and effective as hyaluronic acid 0.2% for the control of subjective and objective symptoms of dry eye?
100 Clinical Results associated with Opocrin SpA
0 Patents (Medical) associated with Opocrin SpA
100 Deals associated with Opocrin SpA
100 Translational Medicine associated with Opocrin SpA